Pennsylvania-based Lannett Co. Inc. (NYSE: LCI) has received approval from the U.S. Food and Drug Administration to manufacture its Numbrino topical anesthetic product at its facility in Seymour. The company also plans to transfer the production of its other liquid drug products to the plant.
Vice President of Operations Grant Brock said the company recently completed the build-out of its liquid drug capabilities at the Seymour plant.
The 397,000-square-foot facility currently employs about 420 workers, and Brock says there are plans for growth.
“We expect to add jobs at the Seymour plant in the future,” Brock said. “This is based on the ramp up of production of Numbrino and our other liquid and suspension drug products, as well as our efforts to expand further our contract development and manufacturing business, which is currently about 20% of the plant’s output and expected to generate continued growth in both plant output and revenue.”
A specific number of potential new jobs was not provided.
Lannett previously manufactured Numbrino and other liquid drug products at its plant in Carmel, N.Y. The company said that facility was sold earlier this year as part of a restructuring and cost reduction plan.
Chief Executive Officer Tim Crew said at the time of the sale that the buyer would continue to produce certain Lannett products for up to 18 months. With the FDA approval, the company says it now only needs less than 10 months of production support.
Lannett company develops, manufactures, packages, and distributes generic pharmaceutical products, both liquid and solid.
With the sale of the New York plant, the Seymour facility is the company’s only manufacturing location. Lannett also has a research and development facility in Philadelphia and its headquarters in the Philly suburb of Trevose.